OBI Pharma

OBI Pharma, Inc., a clinical stage oncology company, researches and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company's pipeline products include Adagloxad simolenin, which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424, which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of solid tumors; OBI-902 and OBI-904 that are in preclinical stage for the treatment of solid tumors; OBI-999 is a novel first-in-class Antibody Drug Conjugate (ADC) with a proprietary linker technology that provides a consistent Drug-to-Antibody ratio (DAR) for cancer treatment; and BsADC which is in discovery stage for the treatment of solid tumors. It also engages in investing and trading; and manufacture and wholesale of western medicines, as well as research and development of biotechnology. OBI Pharma, Inc. was founded in 2002 and is headquartered in Taipei, Taiwan.